Omeprazole + Clarithromycin + Amoxicillin combination regimen - DAVA Pharmaceuticals

Drug Profile

Omeprazole + Clarithromycin + Amoxicillin combination regimen - DAVA Pharmaceuticals

Alternative Names: Omeclamox-Pak

Latest Information Update: 25 Feb 2015

Price : $50

At a glance

  • Originator DAVA Pharmaceuticals
  • Developer Pernix Therapeutics Holdings
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antibacterials; Antiulcers; Macrolides; Penicillins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 50S ribosomal subunit inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Helicobacter infections

Most Recent Events

  • 16 Dec 2014 GastroEntero Logic LLC files sNDA for revisions to the labelling of Omeclamox®-Pak in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top